RCAN1 antibody (C-Term)
Quick Overview for RCAN1 antibody (C-Term) (ABIN358861)
Target
See all RCAN1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Specificity
- This antibody reacts to DSCR1.
-
Purification
- Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
-
Immunogen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human DSCR1.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
-
ELISA: 1/1,000. Western blotting: 1/100 - 1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
-
- RCAN1 (Regulator of Calcineurin 1 (RCAN1))
-
Alternative Name
- Calcipressin-1
-
Background
- DSCR1 interacts with calcineurin A and inhibits calcineurin-dependent signaling pathways, possibly affecting central nervous system development. The gene for this protein is located in the minimal candidate region for the Down syndrome phenotype, and is overexpressed in the brain of Down syndrome fetuses. Chronic overexpression of DSCR1 may lead to neurofibrillary tangles such as those associated with Alzheimer disease.Synonyms: ADAPT78, CSP1, DSC1, DSCR1, Down syndrome critical region protein 1, Myocyte-enriched calcineurin-interacting protein 1, RCAN1, Regulator of calcineurin 1
-
Gene ID
- 1827, 9606
-
UniProt
- P53805
-
Pathways
- Regulation of Muscle Cell Differentiation, Skeletal Muscle Fiber Development
Target
-